13F Holdings
中文EN

URGN UroGen Pharma Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1668243 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY159.3%
TTM net income YoY60.1%
TTM EPS YoY—
Revenue 3-yr CAGR47.9%
Net income 3-yr CAGR—

Margins

Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
FCF margin-52.8%
EBITDA margin-12.2%

Returns

ROE—
ROA-28.8%
ROIC (approx.)—
Asset turnover1.10x

Leverage & solvency

Liabilities / assets146.1%
Debt / equity—
Current ratio3.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.01x
Accruals ratio28.9%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$109.79M$90.40M$82.71M$64.36M$48.04M
Cost of revenue$12.45M$8.88M$9.36M$7.65M$5.16M
Gross profit$97.34M$81.52M$73.35M$56.70M$42.88M
R&D expense$67.11M$57.15M$45.61M$52.91M$47.64M
SG&A expense$155.10M$121.15M$93.27M$82.84M$87.53M
Operating income-$124.86M-$96.78M-$65.54M-$79.04M-$92.29M
Pretax income-$153.42M-$124.04M-$98.32M-$108.03M-$109.37M
Income tax$78,000$2.83M$3.92M$1.75M$1.45M
Net income-$153.49M-$126.87M-$102.24M-$109.78M-$110.82M
EBITDA-$124.56M-$96.45M-$64.73M-$78.12M-$91.46M
EPS (basic)-3.19-2.96-3.55-4.81-4.96
EPS (diluted)————-4.96
Weighted avg. shares (diluted)————22.35M
Balance sheet
Cash & equivalents$110.75M$171.99M$95.00M$55.41M$44.36M
Short-term investments$9.71M$110.67M$56.16M$44.56M$44.78M
Receivables$33.08M$20.30M$15.44M$12.70M$11.72M
Inventory$16.46M$9.23M$5.67M$4.33M$4.83M
Current assets$186.02M$276.13M$169.19M$128.91M$114.39M
PP&E, net$637,000$655,000$689,000$1.30M$1.97M
Total assets$200.46M$285.71M$178.31M$135.62M$119.75M
Current liabilities$46.42M$45.95M$31.21M$23.92M$22.38M
Long-term debt$122.21M$121.73M$98.55M$97.54M$0
Total debt$122.21M$121.73M$98.55M$97.54M$0
Total liabilities$305.93M$294.51M$243.52M$224.98M$111.33M
Shareholders' equity-$105.47M-$8.80M-$65.21M-$89.36M$8.41M
Net debt$11.46M-$50.25M$3.55M$42.13M-$44.36M
Shares outstanding48.35M42.23M32.49M23.13M22.46M
Cash flow statement
Operating cash flow-$162.44M-$96.77M-$76.38M-$87.56M-$84.89M
Capital expenditure$289,000$295,000$194,000$254,000$752,000
Free cash flow-$162.73M-$97.06M-$76.57M-$87.81M-$85.64M
Investing cash flow$61.56M-$20.61M-$953,000$1.06M$4.07M
Financing cash flow$39.92M$194.62M$116.93M$97.13M$72.32M
Depreciation & amortization$307,000$329,000$802,000$924,000$831,000
Stock-based compensation$11.96M$13.11M$9.34M$10.58M$23.11M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.